Effect of low-density lipoprotein cholesterol lowering by ezetimibe/simvastatin on outcome incidence: Overview, meta-analyses, and meta-regression analyses of randomized trials

Clinical Cardiology

Volumn 38, Issue 12, 2015, Pages 763-769

  Thomopoulos, Costas ^a   Skalis, George ^a   Michalopoulou, Helena ^a   Tsioufis, Costas ^b   Makris, Thomas ^a  

^a HELENA VENIZELOU HOSPITAL   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

EZETIMIBE PLUS SIMVASTATIN; PLACEBO; EZETIMIBE; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN;

CEREBROVASCULAR ACCIDENT; CONTROLLED CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG SAFETY; HUMAN; INCIDENCE; ISCHEMIC HEART DISEASE; LIVER DISEASE; META ANALYSIS; MYOPATHY; NEOPLASM; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK REDUCTION; SYSTEMATIC REVIEW; CARDIOVASCULAR DISEASES; COMBINATION DRUG THERAPY; COMPLICATION; DRUG EFFECTS; HYPERCHOLESTEROLEMIA; TREATMENT OUTCOME;

ANTICHOLESTEREMIC AGENTS; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; DRUG THERAPY, COMBINATION; EZETIMIBE; HUMANS; HYPERCHOLESTEROLEMIA; INCIDENCE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SIMVASTATIN; TREATMENT OUTCOME;

EID: 84956595028     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.22441     Document Type: Review

References (24)

1. Baigent C, Blackwell L, Emberson J, et al,; Cholesterol Treatment Trialists' Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet. 2010; 376: 1670-1681.
2. Di Napoli P, Taccardi AA, Oliver M, et al., Statins and stroke: evidence for cholesterol-independent effects. Eur Heart J. 2002; 23: 1908-1921.
3. Stone NJ, Robinson JG, Lichtenstein AH, et al,; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines [published correction appears in J Am Coll Cardiol. 2014;63(25 part B):3024-3025]. J Am Coll Cardiol. 2014; 63 (25 part B): 2889-2934.
4. Morrone D, Weintraub WS, Toth PP, et al., Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: a pooled analysis of over 21 000 subjects from 27 clinical trials. Atherosclerosis. 2012; 223: 251-261.
5. Mihaylova B, Emberson J, Blackwell L, et al,; Cholesterol Treatment Trialists' Collaborators. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012; 380: 581-590.
6. Catapano AL, Farnier M, Foody JM, et al., Combination therapy in dyslipidemia: where are we now? Atherosclerosis. 2014; 237: 319-335.
7. Moher D, Liberati A, Tetzlaff J, et al,; PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement. PLoS Med. 2009; 6:e1000097.
8. Kastelein JJ, Akdim F, Stroes ES, et al,; ENHANCE Investigators. Simvastatin with or without ezetimibe in familial hypercholesterolemia [published correction appears in N Engl J Med. 2008;358:1977]. N Engl J Med. 2008; 358: 1431-1443.
9. Cannon CP, Blazing MA, Giugliano RP, et al., Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015; 372: 2387-2397.
10. Rossebø AB, Pedersen TR, Boman K, et al,; SEAS Investigators. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med. 2008; 359: 1343-1356.
11. Baigent C, Landray MJ, Reith C, et al,; SHARP Investigators. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011; 377: 2181-2192.
12. West AM, Anderson JD, Meyer CH, et al., The effect of ezetimibe on peripheral arterial atherosclerosis depends upon statin use at baseline. Atherosclerosis. 2011; 218: 156-162.
13. Fleg JL, Mete M, Howard BV, et al., Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes: the SANDS (Stop Atherosclerosis in Native Diabetics Study) trial. J Am Coll Cardiol. 2008; 52: 2198-2205.
14. Lewington S, Whitlock G, Clarke R, et al,; Prospective Studies Collaboration. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55 000 vascular deaths [published correction appears in Lancet. 2008;372:292]. Lancet. 2007; 370: 1829-1839.
15. Kjekshus J, Apetrei E, Barrios V, et al,; CORONA Group. Rosuvastatin in older patients with systolic heart failure. N Engl J Med. 2007; 357: 2248-2261.
16. Amarenco P, Bogousslavsky J, Callahan A 3rd, et al,; Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006; 355: 549-559.
17. Vedre A, Gurm HS, Froehlich JB, et al,; GRACE Investigators. Impact of prior statin therapy on arrhythmic events in patients with acute coronary syndromes (from the Global Registry of Acute Coronary Events [GRACE]). Am J Cardiol. 2009; 104: 1613-1617.
18. Robinson JG, Smith B, Maheshwari N, et al., Pleiotropic effects of statins: benefit beyond cholesterol reduction? A meta-regression analysis. J Am Coll Cardiol. 2005; 46: 1855-1862.
19. Thomopoulos C, Parati G, Zanchetti A,. Effects of blood pressure lowering on outcome incidence in hypertension: 3. Effects in patients at different levels of cardiovascular risk-overview and meta-analyses of randomized trials. J Hypertens. 2014; 32: 2305-2314.
20. Stein EA, Raal FJ,. Targeting LDL: is lower better and is it safe? Best Pract Res Clin Endocrinol Metab. 2014; 28: 309-324.
21. Robinson JG, Colhoun HM, Bays HE, et al., Efficacy and safety of alirocumab as add-on therapy in high-cardiovascular-risk patients with hypercholesterolemia not adequately controlled with atorvastatin (20 or 40 mg) or rosuvastatin (10 or 20 mg): design and rationale of the ODYSSEY OPTIONS studies. Clin Cardiol. 2014; 37: 597-604.
22. Robinson JG, Rogers WJ, Nedergaard BS, et al., Rationale and design of LAPLACE-2: a phase 3, randomized, double-blind, placebo- and ezetimibe-controlled trial evaluating the efficacy and safety of evolocumab in subjects with hypercholesterolemia on background statin therapy. Clin Cardiol. 2014; 37: 195-203.
23. Cho L, Rocco M, Colquhoun D, et al., Design and rationale of the GAUSS-2 study trial: a double-blind, ezetimibe-controlled phase 3 study of the efficacy and tolerability of evolocumab (AMG 145) in subjects with hypercholesterolemia who are intolerant of statin therapy. Clin Cardiol. 2014; 37: 131-139.
24. Kashani A, Sallam T, Bheemreddy S, et al., Review of side-effect profile of combination ezetimibe and statin therapy in randomized clinical trials. Am J Cardiol. 2008; 101: 1606-1613.